Upadacitinib for refractory ulcerative colitis with primary nonresponse to infliximab and vedolizumab:A case report
作者机构：Department of GastroenterologyShenzhen HospitalSouthern Medical UniversityShenzhen 518100Guangdong ProvinceChina The First Clinical Medical SchoolSouthern Medical UniversityGuangzhou 510515Guangdong ProvinceChina
出 版 物：《World Journal of Clinical Cases》 (世界临床病例杂志)
年 卷 期：2024年第12卷第9期
页 面：1685-1690页
核心收录：
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Supported by Shenzhen Science and Technology Program,No.JCYJ20220530154013031 Guangdong Province Health and Health Appropriate Technology Promotion Project,No.2023385 Guangdong Province Grassroots Science Popularization Action Plan,No.20240205
主 题：Upadacitinib Refractory ulcerative colitis Primary nonresponse Infliximab Vedolizumab Case report
摘 要：BACKGROUND Many patients with ulcerative colitis(UC)do not respond well to,or tolerate conventional and biological *** is currently no consensus on the treatment of refractory *** have demonstrated that the selective Janus kinase 1 inhibitor upadacitinib,a small-molecule drug,is effective and safe for treating ***,no studies have revealed that upadacitinib is effective in treating refractory UC with primary nonresponse to infliximab and *** SUMMARY We report the case of a 44-year-old male patient with a chief complaint of bloody diarrhoea with mucus and pus,in addition to *** patient had recurrent disease after receiving mesalazine,prednisone,azathioprine,infliximab and vedolizumab over four *** on the endoscopic findings and pathological biopsy,the patient was diagnosed with refractory *** particular,the patient showed primary nonresponse to infliximab and *** on the patient’s history and recurrent disease,we decided to administer *** hospitalisation,the patient was received upadacitinib under our *** weeks after the initiation of upadacitinib treatment,the patient’s symptoms and endoscopic findings improved *** notable adverse reactions have been reported to *** Our case report suggests that upadacitinib may represent a valuable strategy for treating refractory UC with primary nonresponse.
维普期刊数据库